Cancer drug tazemetostat gets Long-Term safety check in rollover trial
Disease control
Completed
This study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC